Release
2021/06/04
OSAKA, Japan, June, 4, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. ; hereafter “Shionogi”) is pleased to announce that Shionogi has signed a memorandum of understanding (MoU) to World Anti-Doping Agency (WADA) on the prevention of misuse and abuse of medicines for doping in sports.
In addition to commercially available medicines, doping in sports is often misused or abused by compounds in the development stage for which detection methods have not yet been widely recognized or detected. The misuse and abuse of medicines and compounds for doping in sports can harm the health and fair competitiveness of athletes in the sports world.
Shionogi affirms WADA’s efforts to prevent misuse and abuse of medicines for doping, and thus have signed an MoU with WADA. Under the MoU, Shionogi will support WADA in its fight against doping in sports by reviewing any of its compounds in development with the potential for sports-related abuse and sharing relevant information to WADA for preventing misuse and abuse of medicines for doping in sports.
Shionogi is committed to discovering and developing pharmaceutical products as well as to ensuring the correct use of products in The Company Policy "supply the best possible medicine to protect the health and wellbeing of the patients we serve." Shionogi hopes that athletes will maintain their health and play sports under fair conditions. Shionogi would like to fulfill its social responsibilities as a pharmaceutical company by sharing information on compounds under development.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Iquiry Form : https://www.shionogi.com/global/en/contact.html
About World Anti-Doping Agency (WADA)
The World Anti-Doping Agency (WADA) is the international independent organization created in 1999 to promote, coordinate and monitor the fight against doping in sport in all its forms. The Agency is composed and funded equally by the sports movement and governments of the world. Its key activities include scientific research, education, development of anti-doping capacities and monitoring of the World Anti-Doping Code – the first document harmonizing regulations regarding anti-doping in all sports and all countries.
Website https://www.wada-ama.org/